Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Target to B! substudy on SARS-CoV-2 immunity in immunosuppressed autoimmune disease patients
NL-OMON55289Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2020
- Countries
- 1
01
Overview
Open-label trial of SARS-CoV-2 vaccine in coronavirus disease 2019 (COVID-19) (3 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoints: Serologic response after vaccination and SARS-CoV-2-specific B-cell and T-cell responses. Started Oct 2020; status: recruiting.
02
Drugs
SARS-CoV-2 vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON55289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55289.